- Home
- ADCT vs DAVA Comparison
ADCT vs DAVA Comparison
Compare ADCT & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- DAVA
- Stock Information
- Founded
- ADCT 2011
- DAVA 2000
- Country
- ADCT Switzerland
- DAVA United Kingdom
- Employees
- ADCT N/A
- DAVA N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- DAVA EDP Services
- Sector
- ADCT Health Care
- DAVA Technology
- Exchange
- ADCT Nasdaq
- DAVA Nasdaq
- Market Cap
- ADCT 454.5M
- DAVA 503.6M
- IPO Year
- ADCT 2020
- DAVA 2018
- Fundamental
- Price
- ADCT $4.40
- DAVA $6.36
- Analyst Decision
- ADCT Strong Buy
- DAVA Buy
- Analyst Count
- ADCT 6
- DAVA 8
- Target Price
- ADCT $7.60
- DAVA $18.14
- AVG Volume (30 Days)
- ADCT 759.6K
- DAVA 1.4M
- Earning Date
- ADCT 11-10-2025
- DAVA 11-11-2025
- Dividend Yield
- ADCT N/A
- DAVA N/A
- EPS Growth
- ADCT N/A
- DAVA 58.26
- EPS
- ADCT N/A
- DAVA 0.25
- Revenue
- ADCT $75,209,000.00
- DAVA $1,015,391,026.00
- Revenue This Year
- ADCT $11.78
- DAVA N/A
- Revenue Next Year
- ADCT $4.83
- DAVA $3.81
- P/E Ratio
- ADCT N/A
- DAVA $24.94
- Revenue Growth
- ADCT 6.35
- DAVA 1.07
- 52 Week Low
- ADCT $1.05
- DAVA $6.03
- 52 Week High
- ADCT $4.80
- DAVA $34.94
- Technical
- Relative Strength Index (RSI)
- ADCT 58.45
- DAVA 31.30
- Support Level
- ADCT $3.95
- DAVA $6.03
- Resistance Level
- ADCT $4.29
- DAVA $6.45
- Average True Range (ATR)
- ADCT 0.28
- DAVA 0.36
- MACD
- ADCT 0.03
- DAVA -0.07
- Stochastic Oscillator
- ADCT 89.02
- DAVA 8.93
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.